Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Cecilia Orbegoso"'
Autor:
Emuella Flood, Anna Krasnow, Cecilia Orbegoso, Stella Karantzoulis, Julie Bailey, Solène Bayet, Arthur Elghouayel, Andrew Foxley, Roberto Sommavilla, Gaia Schiavon
Publikováno v:
PLoS ONE, Vol 18, Iss 1, p e0280259 (2023)
BackgroundDesigning clinical trials with the emphasis on the patient-centered approach and focusing on clinical outcomes that are meaningful to patients is viewed as a priority by drug developers, regulatory agencies, payers, clinicians, and patients
Externí odkaz:
https://doaj.org/article/5be0cc54212f40018a545151da002e00
Autor:
Kamal S. Saini, Begoña de las Heras, Ruth Plummer, Victor Moreno, Marco Romano, Javier de Castro, Philippe Aftimos, Judy Fredriksson, Gouri Shankar Bhattacharyya, Martin Sebastian Olivo, Gaia Schiavon, Kevin Punie, Jesus Garcia-Foncillas, Ernesto Rogata, Richie Pfeiffer, Cecilia Orbegoso, Kenneth Morrison, Giuseppe Curigliano, Lynda Chin, Monika Lamba Saini, Øystein Rekdal, Steven Anderson, Javier Cortes, Manuela Leone, Janet Dancey, Chris Twelves, Ahmad Awada
Publikováno v:
JCO Global Oncology, Vol , Iss 6, Pp 1357-1362 (2020)
Externí odkaz:
https://doaj.org/article/e753a4f9fda043498869674261249653
Autor:
Andreas Heindl, Adnan Mujahid Khan, Daniel Nava Rodrigues, Katherine Eason, Anguraj Sadanandam, Cecilia Orbegoso, Marco Punta, Andrea Sottoriva, Stefano Lise, Susana Banerjee, Yinyin Yuan
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-14 (2018)
Cancer cells can actively engage in overcoming microenvironmental constraints such as tissue stiffness through adapting their shapes; however it is unclear how microenvironmental cells shape cancer nuclear morphology in human tumors in situ. Here the
Externí odkaz:
https://doaj.org/article/80aafabf129a42f2a86063973bcb2266
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Journal of Engineering Education Transformations; Jan2023, Vol. 36 Issue 3, p68-75, 8p
Publikováno v:
Cancer Breaking News. 5:41-44
No abstract available
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::576dbdde6ce4562e2191cfe69c1fdc96
https://doi.org/10.19156/cbn.2017.0059
https://doi.org/10.19156/cbn.2017.0059
Autor:
Sarah Taylor, Jurjees Hasan, Andrew R Clamp, Marcia Hall, Caroline Dive, Gordon J. S. Rustin, Susana Banerjee, Cong Zhou, Alexander R. Lyon, Jonathan Tugwood, Gordon C Jayson, Robert D. Morgan, Cecilia Orbegoso
Publikováno v:
Gynecologic oncology. 156(3)
Objective Vascular co-option is a resistance mechanism to anti-angiogenic agents, but combinations of anti-vascular agents may overcome this resistance. We report a phase 1b and randomised phase 2 trial to determine the safety and efficacy of pazopan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::767f7b5750005113ec0f4c41fb4e55ff
https://pubmed.ncbi.nlm.nih.gov/31932108
https://pubmed.ncbi.nlm.nih.gov/31932108
Autor:
Pascal Hammel, Sandrine Faivre, Thierry André, Aimery de Gramont, Benoist Chibaudel, Sihem Sebbagh, Olivia Hentic, Cecilia Orbegoso, Julia Roux, Eric Raymond, Armand de Gramont, Chantal Dreyer, Cindy Neuzillet
Publikováno v:
Acta Oncologica. 55:1168-1174
Gemcitabine (GEM)-platinum chemotherapy stands as first-line therapy for patients with recurrent/advanced biliary tract cancer (BTC), yielding progression-free survival (PFS) of 3.4-6.4 months. No standard second-line chemotherapy after GEM-platinum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c9ecf371b20c569ba568067fc3a1453
https://doi.org/10.1080/0284186x.2016.1191670
https://doi.org/10.1080/0284186x.2016.1191670
Immunotherapy has been proven effective in several tumours, hence diverse immune checkpoint inhibitors are currently licensed for the treatment of melanoma, kidney cancer, lung cancer and most recently, tumours with microsatellite instability. There
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15b870187dcbf55f01ae9dc85ab202cd
https://europepmc.org/articles/PMC6277269/
https://europepmc.org/articles/PMC6277269/
Autor:
Wolfram Brugger, Cecilia Orbegoso, James Paul, Liz-Anne Lewsley, Udai Banerji, C. Cambell, Rebecca Kristeleit, R.M. Glasspool, Andrew R Clamp, Jonathan Krell, L. Chudleigh, R. Herbertson, Susana Banerjee, C. Shepherd, Aishah Hanif, C. Green, Charlie Gourley, Iain A. McNeish
Publikováno v:
Annals of Oncology. 30:v403-v404
Background OCTOPUS, an NCRI investigator-initiated umbrella phase II trial, tests the addition of targeted agents to weekly paclitaxel (wP) in recurrent platinum-resistant/refractory ovarian cancer. The first agent tested is the dual mTORC1/mTORC2 in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6a1892c26fc6f8796a6bc764973680d7
https://doi.org/10.1093/annonc/mdz250.001
https://doi.org/10.1093/annonc/mdz250.001